First, a confession for a peptide site. NAD+ is not a peptide. It is a coenzyme made from vitamin B3. We cover it anyway because it sits right next to peptides in every wellness clinic and every “longevity stack,” and because people ask about it constantly. The story here is a lot like glutathione. The biology is real and important. The IV drip is where the evidence gets thin.
Split by route. Oral precursors like NR and NMN have dozens of human trials. They reliably raise NAD+ in the blood, but their effects on health have been modest or mixed. IV NAD+, the thing clinics sell, has almost no human research. We found three small studies, none showing a clinical benefit. And for addiction, a common sales pitch, there are no controlled trials at all.
NAD+ stands for nicotinamide adenine dinucleotide. Every cell in your body uses it. It has two big jobs. It shuttles electrons in the reactions that turn food into energy. And it is used up as fuel by enzymes that repair DNA and regulate aging, including the sirtuins you may have heard about.
You will often read that NAD+ “drops 50% by middle age.” Be careful with that. The decline is well shown in mice. In humans, a 2025 review in Nature Metabolism said the drop has only been seen consistently in a limited number of studies and that human tissue data is sparse. It probably declines in some tissues. It is not a settled number.
NAD+ was discovered in the early 1900s and is textbook biochemistry. The IV drip trend is much newer. Its roots go back to a 1961 report claiming IV NAD+ helped people withdraw from alcohol and drugs. That report was not controlled. Modern IV clinics revived the idea and expanded it into anti-aging, energy and recovery.
Here is the part most clinics leave out. When NAD+ goes into your vein, most of it does not go straight into your cells. A 2019 study infused 750 mg slowly over six hours into healthy men. For the first two hours, NAD+ disappeared from the blood almost completely. After that, levels rose, but so did its breakdown products. The researchers concluded much of the NAD+ was being broken down outside cells, likely by an enzyme called CD38.
The current model is that cells mostly take up the smaller pieces and rebuild NAD+ inside. So “100% bioavailable straight into your cells” is not accurate. No human study has shown that an IV drip raises NAD+ inside tissues.
IV NAD+ in humans comes down to three small studies.
The 2019 study above measured blood levels only, with no health outcomes. A 2024 randomized trial, still a preprint and funded by a company that sells NR, compared IV NAD+ to IV NR. The NAD+ infusions caused more and worse side effects, took longer, and raised white blood cells, a sign of inflammation. A 2026 chart review at a wellness chain, just 14 people, found NAD+ caused moderate to severe stomach symptoms, a faster heart rate and chest pressure.
For addiction, the evidence is case reports going back to 1961. No randomized trial exists.
Oral precursors have far more research. NR and NMN reliably raise blood NAD+ by about 1.5 to 2 times. But a 12-week NR trial in men with obesity found no improvement in insulin sensitivity. A small NMN study in prediabetic women did improve muscle insulin sensitivity. Overall, the results are modest.
Energy, anti-aging, mental clarity, hangover recovery, athletic recovery and addiction “detox.” The drips usually run one to four hours or more.
The infusion itself is famously unpleasant when it runs fast. Flushing, chest tightness or pressure, nausea and cramping are common. Slowing the drip usually helps. In the slow six-hour study, there were no side effects.
The bigger risk is quality. In January 2026, the FDA sent a warning letter to a facility after three patients went to the ER with low blood pressure, shaking chills and body aches after a compounded NAD+ dose. An unopened vial from that batch tested high for bacterial endotoxin. If that sounds familiar, it is the same problem we covered with compounded glutathione.
Long-term effects of repeated high-dose NAD+ are unknown. There is also a theoretical question about whether boosting NAD+ could support cancer cells, which have high energy needs. The precursor trials have not shown this, but they are short.
Reporting, not a recommendation. Clinic and marketing sites describe IV doses of roughly 250 to 1,000 mg per session, often as a “loading” series over several days. Injections under the skin are described at roughly 50 to 200 mg. These numbers come from marketing, not research. We do not give injection steps.
There is no FDA-approved NAD+ drug. Injectable NAD+ is compounded. NAD is in the FDA’s Category 1 for compounding pharmacies, which means “under evaluation.” That status lets pharmacies compound it for now while the review continues. It is not approval, and it can change. Back in 2017, the FDA actually proposed not adding NAD to the approved compounding list, and it still has not been added.
Larger outsourcing facilities are a different story. The FDA’s January 2026 warning letter said NAD+ from those facilities does not qualify for their compounding exemption.
On the oral side, NMN had a rocky few years. The FDA said in 2022 that NMN could not be sold as a supplement. It reversed that in September 2025, so NMN is legal as a supplement in the US again.
Is NAD+ a peptide? No. It is a coenzyme made from vitamin B3.
Does an IV drip raise NAD+ in my cells? It raises NAD+ and its breakdown products in the blood. Much of it is broken down outside cells first. No human study has shown higher tissue levels or a health benefit.
Why does the drip feel so bad? Fast infusion commonly causes chest tightness, nausea, flushing and cramping. Slowing it usually helps.
Does IV NAD+ treat addiction? Unproven. The evidence is uncontrolled case reports with no randomized trials.
Is IV NAD+ better than NR or NMN pills? No trial shows better outcomes. The pills have far more research behind them.
Is NAD+ injection legal? It is not FDA-approved. Pharmacies can currently compound it while it is under evaluation, but that can change.
Is NMN legal as a supplement? Yes, since the FDA’s September 2025 reversal.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.